Treatment of Type 2 Diabetes With FTY720

Abstract

The present disclosure provides therapeutic methods for prevention and treatment of type-2 diabetes comprising administering to the subject an effective amount of FTY720 or an analog.

What is claimed is: 
     
         1 . A method for treating a subject having type-2 diabetes comprising administering to the subject, a composition comprising an effective amount of 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol (FTY720) or a pharmaceutically acceptable salt thereof, or 2-amino-2-(hydroxymethyl)-4-(4-octylphenyl)butyl dihydrogen phosphate (FTY720-P) or a pharmaceutically acceptable salt thereof. 
     
     
         2 . The method according to  claim 1 , wherein the effective dose is between about 0.0001 mg/kg/day and about 1 mg/kg/day. 
     
     
         3 . The method according to  claim 1 , wherein the unit dose is between about 0.01 mg to about 70 mg. 
     
     
         4 . The method according to  claim 1 , wherein the method further comprises administration of an additional therapeutic agent wherein the additional therapeutic agent is metformin, repaglinide, nateglinde, chloropropamide, glimepiride, glipizide, glyburide, tolazamide, tolbutamide, pioglitazone, rosiglitazone, acarbose, miglitolan additional agent wherein the metformin, repaglinide, nateglinde, chloropropamide, glimepiride, glipizide, glyburide, tolazamide, tolbutamide, pioglitazone, rosiglitazone, acarbose, miglitol, sitagliptin, saxagliptin, bromocriptine, liraglutide, or pramlintide acetate. 
     
     
         5 . The method according to  claim 1 , wherein the method further comprises administration of an additional therapeutic agent wherein the additional therapeutic agent is insulin. 
     
     
         6 . A method for preserving or increasing the mass of functional beta-cells in a subject having type-2 diabetes comprising administering to the subject, a composition comprising an effective amount of FTY720 or a pharmaceutically acceptable salt thereof, or FTY720-P or a pharmaceutically acceptable salt thereof. 
     
     
         7 . The method according to  claim 6 , wherein the effective dose is between about 0.0001 mg/kg/day and about 1 mg/kg/day. 
     
     
         8 . The method according to  claim 6 , wherein the unit dose is between about 0.01 mg to about 70 mg. 
     
     
         9 . The method according to  claim 6 , wherein the method further comprises administration of an additional therapeutic agent wherein the additional therapeutic agent is metformin, repaglinide, nateglinde, chloropropamide, glimepiride, glipizide, glyburide, tolazamide, tolbutamide, pioglitazone, rosiglitazone, acarbose, miglitolan additional agent wherein the metformin, repaglinide, nateglinde, chloropropamide, glimepiride, glipizide, glyburide, tolazamide, tolbutamide, pioglitazone, rosiglitazone, acarbose, miglitol, sitagliptin, saxagliptin, bromocriptine, liraglutide, or pramlintide acetate. 
     
     
         10 . The method according to  claim 6 , wherein the method further comprises administration of an additional therapeutic agent wherein the additional therapeutic agent is insulin. 
     
     
         11 . A method for increasing insulin levels in a subject having type-2 diabetes comprising administering to the subject a composition comprising an effective amount of FTY720 or a pharmaceutically acceptable salt thereof, or FTY720-P or a pharmaceutically acceptable salt thereof. 
     
     
         12 . The method according to  claim 11 , wherein the effective dose is between about 0.0001 mg/kg/day and about 1 mg/kg/day. 
     
     
         13 . The method according to  claim 11 , wherein the unit dose is between about 0.01 mg to about 70 mg. 
     
     
         14 . The method according to  claim 11 , wherein the method further comprises administration of an additional therapeutic agent wherein the additional therapeutic agent is metformin, repaglinide, nateglinde, chloropropamide, glimepiride, glipizide, glyburide, tolazamide, tolbutamide, pioglitazone, rosiglitazone, acarbose, miglitolan additional agent wherein the metformin, repaglinide, nateglinde, chloropropamide, glimepiride, glipizide, glyburide, tolazamide, tolbutamide, pioglitazone, rosiglitazone, acarbose, miglitol, sitagliptin, saxagliptin, bromocriptine, liraglutide, or pramlintide acetate.